For Healthcare Professionals

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies


About the study

This is a Phase I open-label, multi-center study of GS-9716 tested either as monotherapy or in combination with other anti-cancer agents in patients with advanced solid malignancies. Primary objectives are to define the maximum tolerated dose (MTD) or maximum administered dose of GS-9716, and characterize the safety and tolerability of GS-9716 as monotherapy and in combination with anti-cancer therapies.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Key Inclusion Criteria:

General Inclusion Criteria (all cohorts):

  1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  2. Measurable disease per RECIST version 1.1
  3. Adequate hematology, renal and hepatic function
  4. Left ventricular ejection fraction (LVEF) ≥ 50%
  5. Patients with brain metastases may be enrolled only if treated, nonprogressive, asymptomatic and not taking high dose steroids for at least 4 weeks prior to Cycle 1 Day 1 (C1D1)
  6. Individuals of childbearing potential who engage in heterosexual intercourse must agree to use method(s) of contraception, per protocol.
  7. Tissue criteria: must provide sufficient, and adequate tumor tissue sample or agree to have a biopsy taken.

Part A Specific Inclusion Criteria: GS-9716 as monotherapy

Histologically or cytologically confirmed locally advanced or metastatic malignant solid tumor for which no standard therapy is available, standard therapy has failed, or for whom standard-of-care therapy is contraindicated.

Cohorts B1 and C1 Specific Inclusion Criteria:

  1. Histologically or cytologically confirmed unresectable metastatic or locally advanced disease following treatment for metastatic disease including an immune checkpoint inhibitor and a platinum-containing chemotherapy
  2. Patients with actionable genomic alterations must have also received treatment with at least 1 approved therapy appropriate to the genomic alteration unless unavailable or contraindicated

Cohorts B4 and C4 Specific Inclusion Criteria:

Histologically or cytologically confirmed disease based on the most recent analyzed biopsy metastatic disease that is refractory to or relapsed after at least 2 prior standard-of-care chemotherapy regimens, one of which was a taxane (unless contraindicated).


Key Exclusion Criteria:

  1. Prior systemic anti-cancer therapy must meet wash-out criteria outlined in protocol
  2. Treatment with any high dose systemic corticosteroids or nonsystemic radiotherapy within 2 weeks of the first dose of GS-9716 (low dose corticosteroids permitted).
  3. Women who are pregnant or lactating
  4. Patients with active ≥ Grade 2 nausea or vomiting, and/or signs of intestinal obstruction
  5. Known active or chronic hepatitis B or C infection or HIV infection/ HIV positive
  6. Known history of clinically significant cardiovascular disease or heart failure.
  7. Known history of clinically significant active chronic obstructive pulmonary disease or other moderate to severe chronic respiratory illness present within 6 months prior to C1D1
  8. Known history of other clinically significant pulmonary disease or evidence of active pneumonitis
  9. Uncontrolled pleural effusion, pericardial effusion, or ascites
  10. History of clinically significant bleeding, intestinal obstruction, or gastrointestinal (GI) perforation within 6 months prior to C1D1
  11. Infection requiring intravenous anti-infective use within 2 weeks prior to C1D1
  12. Active or history of autoimmune disease or immune deficiency
  13. History of uncured coexisting cancer, not including uncured basal cell carcinoma, cervical cancer in situ, or superficial bladder cancer.

Cohort A Specific Exclusion Criteria: GS-9716 as monotherapy:

Known heart failure or elevated cardiac biomarkers

Cohorts B1 and C1 Specific Exclusion Criteria:

Known hypersensitivity to excipients in study treatments.

Cohorts B4 and C4 Specific Exclusion Criteria:

Prior treatment with sacituzumab govitecan-hziy or a topoisomerase 1 inhibitor or agents targeting Trop-2.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Solid Malignancies

Age (in years)



Phase 1

Participants needed


Est. Completion Date

Jan 31, 2027

Treatment type



Gilead Sciences identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.